{"id":"valacyclovir-zelitrex","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"1-2","effect":"Tremor (at high doses)"},{"rate":"<1","effect":"Confusion or hallucinations (rare, high-dose)"}]},"_chembl":{"chemblId":"CHEMBL1349","moleculeType":"Small molecule","molecularWeight":"324.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valacyclovir is rapidly metabolized to acyclovir in the body. Acyclovir is phosphorylated by viral thymidine kinase in infected cells, then further phosphorylated to the active triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination of viral DNA synthesis. This selectively targets herpesvirus-infected cells while sparing uninfected cells.","oneSentence":"Valacyclovir is a prodrug that is converted to acyclovir, which inhibits viral DNA polymerase to prevent herpesvirus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:56.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Herpes simplex virus (HSV-1 and HSV-2) infection, including genital herpes and cold sores"},{"name":"Varicella-zoster virus (VZV) infection, including shingles (herpes zoster) and chickenpox"},{"name":"Cytomegalovirus (CMV) prophylaxis in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT06914479","phase":"PHASE1","title":"Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-06-01","conditions":"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm","enrollment":11},{"nctId":"NCT03576612","phase":"PHASE1","title":"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2018-02-27","conditions":"Glioma, Malignant","enrollment":41},{"nctId":"NCT01689285","phase":"PHASE1","title":"Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-12","conditions":"Varicella Zoster Virus Infection, Herpes Simplex Virus Infection","enrollment":16},{"nctId":"NCT01364792","phase":"PHASE2","title":"To Rescue Cognition With Valaciclovir","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Schizophrenia, Psychosis","enrollment":24},{"nctId":"NCT01633476","phase":"PHASE2","title":"CMV Modulation of the Immune System in ANCA-associated Vasculitis","status":"UNKNOWN","sponsor":"Professor Lorraine Harper","startDate":"2013-07","conditions":"ANCA Associated Vasculitis, CMV Infection","enrollment":38},{"nctId":"NCT01037712","phase":"PHASE4","title":"In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Viral Disease, Cytomegalovirus Infection","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valacyclovir (ZELITREX)","genericName":"Valacyclovir (ZELITREX)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valacyclovir is a prodrug that is converted to acyclovir, which inhibits viral DNA polymerase to prevent herpesvirus replication. Used for Herpes simplex virus (HSV-1 and HSV-2) infection, including genital herpes and cold sores, Varicella-zoster virus (VZV) infection, including shingles (herpes zoster) and chickenpox, Cytomegalovirus (CMV) prophylaxis in immunocompromised patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}